Rachel Carlson

He told me that the company did a clinical trial to test whether DLX-1 made people hallucinate, and it seemed like it didn't. And now they're testing the drug on patients who have depression.

He told me that the company did a clinical trial to test whether DLX-1 made people hallucinate, and it seemed like it didn't. And now they're testing the drug on patients who have depression.

He told me that the company did a clinical trial to test whether DLX-1 made people hallucinate, and it seemed like it didn't. And now they're testing the drug on patients who have depression.

And again, there's a lot more to learn. And you said other companies are doing things like this also, right? They are. Companies want to develop drugs they can patent so they can get funding for more research. So there are a bunch of groups in this space. Some are just making more traditional psychedelics.

And again, there's a lot more to learn. And you said other companies are doing things like this also, right? They are. Companies want to develop drugs they can patent so they can get funding for more research. So there are a bunch of groups in this space. Some are just making more traditional psychedelics.

And again, there's a lot more to learn. And you said other companies are doing things like this also, right? They are. Companies want to develop drugs they can patent so they can get funding for more research. So there are a bunch of groups in this space. Some are just making more traditional psychedelics.

Some are trying to make shorter acting psychedelics or engineer out potentially negative side effects, like some psychedelics bind to certain heart receptors. So they might want to take that side effect out. And all this kind of exploded around 2019, 2020, with lots of these companies popping up and eventually trying to file these patents for their respective drugs.

Some are trying to make shorter acting psychedelics or engineer out potentially negative side effects, like some psychedelics bind to certain heart receptors. So they might want to take that side effect out. And all this kind of exploded around 2019, 2020, with lots of these companies popping up and eventually trying to file these patents for their respective drugs.

Some are trying to make shorter acting psychedelics or engineer out potentially negative side effects, like some psychedelics bind to certain heart receptors. So they might want to take that side effect out. And all this kind of exploded around 2019, 2020, with lots of these companies popping up and eventually trying to file these patents for their respective drugs.

Yeah, it can get a little complicated since traditional psychedelics have been around for a really long time, and a lot of them come from nature. So I talked to a patent lawyer about this. He focuses on psychedelics. His name's Graham Pachenik.

Yeah, it can get a little complicated since traditional psychedelics have been around for a really long time, and a lot of them come from nature. So I talked to a patent lawyer about this. He focuses on psychedelics. His name's Graham Pachenik.

Yeah, it can get a little complicated since traditional psychedelics have been around for a really long time, and a lot of them come from nature. So I talked to a patent lawyer about this. He focuses on psychedelics. His name's Graham Pachenik.

So Graham told me patent examiners may not always have access to all of the past research out there. And there are people who've argued some companies have gone too far by trying to patent things that they say shouldn't really be patented, like the way the room is set up while patients are getting treatment.

So Graham told me patent examiners may not always have access to all of the past research out there. And there are people who've argued some companies have gone too far by trying to patent things that they say shouldn't really be patented, like the way the room is set up while patients are getting treatment.

So Graham told me patent examiners may not always have access to all of the past research out there. And there are people who've argued some companies have gone too far by trying to patent things that they say shouldn't really be patented, like the way the room is set up while patients are getting treatment.

Yeah, exactly. And so it's still too early to say, but it's possible we could start to see more companies like Delix in the future. If investors are more inclined to put money into drugs that kind of work like psychedelics but don't involve actual psychedelics.

Yeah, exactly. And so it's still too early to say, but it's possible we could start to see more companies like Delix in the future. If investors are more inclined to put money into drugs that kind of work like psychedelics but don't involve actual psychedelics.

Yeah, exactly. And so it's still too early to say, but it's possible we could start to see more companies like Delix in the future. If investors are more inclined to put money into drugs that kind of work like psychedelics but don't involve actual psychedelics.

Yeah, some people definitely feel strongly that the whole experience that comes with these drugs is key when it comes to treating patients. Even David and Eliseo both told me they're not saying that we should replace psychedelics altogether with these non-hallucinogenic compounds. But they are saying that we should develop both things. Here's Eliseo.

Yeah, some people definitely feel strongly that the whole experience that comes with these drugs is key when it comes to treating patients. Even David and Eliseo both told me they're not saying that we should replace psychedelics altogether with these non-hallucinogenic compounds. But they are saying that we should develop both things. Here's Eliseo.